Ask AI

Interactive Tools and Resources for the Current Management of mCRPC: Focus on Radioligand Therapies

Gain expert insights into current and emerging clinical data on radioligand therapies used to manage metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA PET/CT to predict response through an Interactive Decision Support Tool, certified Clinical Focus text module, and accompanying downloadable slides.

Share

Program Content

Activities

Radioligand Tx for mCRPC
Advances in Metastatic Castration-Resistant Prostate Cancer: Focus on Radioligand Therapies
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2025

Expires: March 15, 2026

Activities

Radioligand Therapy Slides
Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer 
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation